EAM Investors LLC Purchases New Position in Scholar Rock Holding Co. (NASDAQ:SRRK)

EAM Investors LLC acquired a new position in Scholar Rock Holding Co. (NASDAQ:SRRK) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 137,861 shares of the company’s stock, valued at approximately $5,958,000. Scholar Rock comprises approximately 0.8% of EAM Investors LLC’s holdings, making the stock its 8th largest position. EAM Investors LLC owned 0.15% of Scholar Rock at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of Scholar Rock by 7.1% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 94,795 shares of the company’s stock valued at $759,000 after purchasing an additional 6,269 shares in the last quarter. Wellington Management Group LLP raised its holdings in Scholar Rock by 16.2% during the third quarter. Wellington Management Group LLP now owns 199,777 shares of the company’s stock valued at $1,600,000 after buying an additional 27,801 shares in the last quarter. Barclays PLC lifted its position in shares of Scholar Rock by 103.4% in the third quarter. Barclays PLC now owns 165,449 shares of the company’s stock worth $1,324,000 after buying an additional 84,118 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Scholar Rock by 8.5% during the 3rd quarter. Geode Capital Management LLC now owns 1,543,025 shares of the company’s stock worth $12,361,000 after acquiring an additional 120,489 shares in the last quarter. Finally, Exome Asset Management LLC acquired a new position in shares of Scholar Rock during the 3rd quarter valued at about $1,115,000. 91.08% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Scholar Rock news, insider Tracey Sacco sold 6,500 shares of Scholar Rock stock in a transaction on Monday, March 24th. The stock was sold at an average price of $33.08, for a total transaction of $215,020.00. Following the completion of the transaction, the insider now directly owns 71,750 shares of the company’s stock, valued at approximately $2,373,490. This trade represents a 8.31 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Jing L. Marantz sold 5,655 shares of the company’s stock in a transaction dated Thursday, January 16th. The stock was sold at an average price of $44.20, for a total transaction of $249,951.00. Following the completion of the sale, the insider now directly owns 67,200 shares in the company, valued at approximately $2,970,240. The trade was a 7.76 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 299,772 shares of company stock worth $11,245,798 over the last 90 days. Corporate insiders own 19.20% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Wedbush restated an “outperform” rating and issued a $50.00 target price on shares of Scholar Rock in a report on Tuesday, March 25th. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $42.67.

Scholar Rock Trading Up 4.5 %

Scholar Rock stock opened at $30.22 on Wednesday. The business has a 50 day moving average price of $33.74 and a two-hundred day moving average price of $34.80. The company has a quick ratio of 3.88, a current ratio of 3.88 and a debt-to-equity ratio of 0.63. The stock has a market cap of $2.86 billion, a price-to-earnings ratio of -12.86 and a beta of 0.56. Scholar Rock Holding Co. has a 12 month low of $6.76 and a 12 month high of $46.98.

Scholar Rock Company Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.